Thursday 16 October, 2025
Objective: To develop a population model to describe the absorption and plasma time profile of glucose when multiple high oral…
Read moreoral presentation
What is the Value of Uncertainty Parameter Estimates provided by Different Population PK Methods?
Thursday 16 October, 2025
PDF of presentation Background In population models, parameter uncertainty is estimated either by posterior distribution of fixed and random effect…
Read moreOverview of oral absorption models and modelling issues
Thursday 16 October, 2025
Clinical trials with description of pharmacokinetics as an objective often have designs that do not allow a detailed description of…
Read moreParallel computing under Linux
Thursday 16 October, 2025
Objectives: According to Moore’s law [1], there is an exponential growth in the number of transistors per integrated circuit over…
Read moreA pharmacodynamic model for Scandinavian Stroke Scale data
Thursday 16 October, 2025
Objectives: Stroke severity is commonly measured on aggregate clinical assessment scales. While such scales are convenient tools in the clinical…
Read moreA PK-PD-disease model to support the design of clinical trials of drugs for the treatment of HIV
Thursday 16 October, 2025
Background: The viral dynamics of HIV infection have been widely studied and expressed as mathematical equations. For most of the…
Read moreGraphical display of population data
Thursday 16 October, 2025
PDF of presentation Graphical displays are important tools for exploration, goodness of fit assessment and presentation in any type of…
Read moreA real time optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics
Thursday 16 October, 2025
PDF of presentation Introduction: Itraconazole is used in the treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Recent…
Read moreProspective assessment of a D-optimal design for a population pharmacokinetic study of enoxaparin
Thursday 16 October, 2025
Background Recently, methods for computing D-optimal designs for population pharmacokinetic experiments have become available. However there are few publications that…
Read moreEstimating population pharmacokinetic parameters when dose and dose-time are not known accurately
Thursday 16 October, 2025
Introduction: Understanding the PKPD relationship of therapeutic agents when used in overdose is paramount for the development of treatment guidelines….
Read more